RSV vaccines have reportedly fallen since U.S. regulators narrowed the recommended age range and frequency for the shots.

These data presented at the CHEST 2024 Annual Meeting, organised by the American College of Chest Physicians. Arexvy is the world’s first RSV vaccine and was approved based on exceptional efficacy in ...

Meanwhile, demand for vaccines targeting respiratory syncytial virus are down in the U.S. Also, if you are uncertain about whether you might have covid or the flu, the newly approved at-home Healgen ...

The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ...

GSK shared new Phase III data on Arexvy, its RSV vaccine, at the 2024 CHEST annual meeting. Results show a single dose of ...

London: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held ...

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST ...

Pfizer has terminated development of its RSV treatment candidate sisunatovir, a viral inhibitor picked up in its up to $525 ...

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...